Duloxetine oral suspension - OWP Pharmaceuticals
Latest Information Update: 28 Aug 2024
At a glance
- Originator OWP Pharmaceuticals
- Class Antidepressants; Antineoplastics; Anxiolytics; Naphthalenes; Non-opioid analgesics; Propanolamines; Small molecules; Thiophenes; Urologics
- Mechanism of Action Adrenergic uptake inhibitors; Norepinephrine plasma membrane transport protein inhibitors; Serotonin plasma membrane transport protein inhibitors; Serotonin uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Generalised anxiety disorder; Major depressive disorder
Most Recent Events
- 28 Aug 2024 No recent reports of development identified for preclinical development in Generalised-anxiety-disorder in USA (PO)
- 28 Aug 2024 No recent reports of development identified for preclinical development in Major depressive disorder in USA (PO)
- 13 Jul 2020 Preclinical trials in Generalised anxiety disorder in USA (PO)